Grant: Engage Grants Program
University of British Columbia
$25,000.00
Characterization of anti-human Granzyme B monoclonal antibody 10C11
FY 2015-16
Summary
It has been demonstrated that granzyme B (GzmB), a cytotoxic serine protease, accumulates in tissues affected by
aging and chronic inflammation and contributes to reduced integrity and impaired wound healing. GzmB is one
of a family of five serine proteases that are now emerging as key targets for drug development. Based on these
findings, the research based biotechnology company, viDA Therapeutics is developing a suite of 'first-in-class
drugs' (small molecule and biological) that inhibit the action of GzmB designed for multiple routes of
administration to treat the various inflammatory and age related conditions. To pursue the effects of biological
inhibition of GzmB, viDA has acquired the anti-human GzmB monoclonal antibody 10C11 (raised in rabbits
against purified human GzmB) and would like to first completely characterize the antibody before conducting
animal trials. At present viDA does not have the resources or expertise to fully characterize the antibody and
would like to enlist the help of Dr. Jamie Piret at the University of British Columbia using a NSERC-Engage
grant to carry out the required characterization.
Program
Engage Grants Program
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
491609-2015
Name nom
Piret, James
Department département
Michael Smith Laboratories
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
1
Nb partie
1
Application title
Characterization of anti-human Granzyme B monoclonal antibody 10C11
Keyword
NSERC
Application summary
It has been demonstrated that granzyme B (GzmB), a cytotoxic serine protease, accumulates in tissues affected by
aging and chronic inflammation and contributes to reduced integrity and impaired wound healing. GzmB is one
of a family of five serine proteases that are now emerging as key targets for drug development. Based on these
findings, the research based biotechnology company, viDA Therapeutics is developing a suite of 'first-in-class
drugs' (small molecule and biological) that inhibit the action of GzmB designed for multiple routes of
administration to treat the various inflammatory and age related conditions. To pursue the effects of biological
inhibition of GzmB, viDA has acquired the anti-human GzmB monoclonal antibody 10C11 (raised in rabbits
against purified human GzmB) and would like to first completely characterize the antibody before conducting
animal trials. At present viDA does not have the resources or expertise to fully characterize the antibody and
would like to enlist the help of Dr. Jamie Piret at the University of British Columbia using a NSERC-Engage
grant to carry out the required characterization.